SAROMICS BIOSTRUCTURES AB

Their core work

Saromics Biostructures is a contract structural biology company based in Lund, Sweden, specializing in protein crystallography and 3D structure determination. They provide structural biology services to research consortia working across diverse life science domains — from enzyme engineering to drug discovery. Their core value lies in resolving molecular structures that inform rational design of biocatalysts, antivirals, and therapeutic compounds. As a specialized SME, they act as a technical service provider embedded within larger research networks.

What they specialise in

How they've shifted over time

With all three projects starting between 2015 and 2017, the timeline is too compressed to identify a clear strategic shift. However, there is a visible broadening pattern: from biocatalysis (BIOCASCADES, 2015) to viral metagenomics (Virus-X, 2016) to pharmaceutical drug design (SAFER, 2017). This suggests Saromics progressively expanded the application domains where they deploy their structural biology platform, moving toward higher-value pharmaceutical applications.

Saromics appears to be moving from basic enzyme characterization toward pharmaceutical and drug design applications, which suggests future collaborations may lean toward medicinal chemistry and receptor biology.

How they like to work

Saromics operates exclusively as a participant, never as a coordinator — consistent with their role as a specialized service provider embedded in larger consortia. With 28 unique partners across just 3 projects, they work in medium-to-large consortia (averaging ~10 partners per project) and do not appear to repeat partners, indicating broad network reach rather than deep bilateral ties. This profile suits organizations seeking reliable structural biology expertise without the overhead of building it in-house.

Saromics has collaborated with 28 unique partners across 12 countries in just 3 projects, reflecting broad European connectivity for a small company. Their Lund base places them within Sweden's strong life science cluster, with consortium ties spanning multiple EU member states.

What sets them apart

Saromics occupies a rare niche as a private SME offering contract structural biology — most protein crystallography capacity in Europe sits within universities or large research institutes. This makes them an attractive consortium partner when projects need dedicated structural biology work packages without relying on academic timelines. Their ability to serve diverse domains (enzymes, viral proteins, drug targets) from a single technical platform makes them unusually versatile for their size.

Highlights from their portfolio

• Virus-X
  Largest funding (EUR 558,175) and most distinctive topic — applying structural biology to novel enzymes discovered through viral metagenomics.
• SAFER
  Closest to pharmaceutical application — selective serotonin receptor agonists represent direct drug design relevance with commercial potential.
• BIOCASCADES
  MSCA training network combining biocatalysis with structural methods, demonstrating Saromics' role in training the next generation of researchers.